[Aztreonam as monotherapy in urinary tract infections with a systemic repercussion in patients with a relative contraindication for the use of aminoglycosides].
A comparative study has been performed to evaluate the clinical efficacy and safety of aztreonam in the treatment of urinary tract infections with systemic affectation, in a group of patients who showed a relative contraindication to be treated with aminoglycosides. The group studied was formed by 30 patients (21 females and 9 males). Mean age of said group was 78 years and percentage of patients over 65 years was 93%. Moreover, 53.3% of patients showed nephropathy, 30% diabetes mellitus and 16.6% hearing disorders. Responsible germ of the infection was identified through blood and urine culture in 24 patients (80%) being the most frequent isolated E. Coli (60%). The cure rate was of 76.6% and improvement rate was 13.3%. Three deaths happened on the studied group (10%). In a patient superinfection due to Enterococcus was detected. There were no significative adverse effects (hypersensibility reactions, hematological disorders, nephrotoxicity or hepatotoxicity). Aztreonam could be an efficacious alternative in the treatment of urinary infection with systemic affectation, caused by gram-negative germs, showing low toxicity.
Pedrajas
J M
JM
Servicio de Medicina Interna III, Hospital Universitario San Carlos, Madrid.
Pieltain
R
R
Mesa
N
N
Ramón
P
P
García
C
C
Pontes
J C
JC
Fernández-Cruz
A
A
D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001398:Aztreonam / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D000075202:Contraindications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001398:Aztreonam
Aztreonam como monoterapia en infecciones del tracto urinario con repercusión sistémica de pacientes con contraindicación relativa para el uso de aminoglucósidos.